Compare UAA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UAA | IMNM |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.5B |
| IPO Year | 2005 | 2020 |
| Metric | UAA | IMNM |
|---|---|---|
| Price | $5.07 | $24.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 10 |
| Target Price | $6.48 | ★ $32.80 |
| AVG Volume (30 Days) | ★ 6.8M | 951.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,966,370,000.00 | $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.57 | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.13 | $8.93 |
| 52 Week High | $8.15 | $30.06 |
| Indicator | UAA | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 32.56 | 42.00 |
| Support Level | $4.83 | $19.28 |
| Resistance Level | $6.13 | $27.14 |
| Average True Range (ATR) | 0.17 | 1.08 |
| MACD | 0.02 | -0.48 |
| Stochastic Oscillator | 14.29 | 1.54 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.